Breaking News Instant updates and real-time market news.

PFE

Pfizer

$35.50

-0.06 (-0.17%)

, JNJ

Johnson & Johnson

$140.01

-1.05 (-0.74%)

19:11
12/07/17
12/07
19:11
12/07/17
19:11

Pfizer consumer unit sale attracts J&J, Glaxo, Sanofi, Bloomberg reports

Pfizer (PFE) expects to receive non-binding offers for its consumer business in early 2018 from global health care and consumer companies, Bloomberg reports, citing people familiar with the matter. Companies including Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Sanofi (SNY), Reckitt Benckiser (RBGLY), and Nestle (NSRGY) are working with advisers as they weigh making a bid for the business, the report says. The unit could draw $15B-$20B in a sale, the report notes.

PFE

Pfizer

$35.50

-0.06 (-0.17%)

JNJ

Johnson & Johnson

$140.01

-1.05 (-0.74%)

GSK

GlaxoSmithKline

$34.84

0.18 (0.52%)

SNY

Sanofi

$43.29

0.12 (0.28%)

RBGLY

Reckitt Benckiser

$17.78

0.21 (1.20%)

NSRGY

Nestle

$86.16

-0.48 (-0.55%)

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

PFE Pfizer
$35.50

-0.06 (-0.17%)

11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
JNJ Johnson & Johnson
$140.01

-1.05 (-0.74%)

10/18/17
ARGS
10/18/17
NO CHANGE
Target $165
ARGS
Buy
Johnson & Johnson price target raised to $165 from $145 at Argus
Argus analyst David Toung raises his price target on Johnson & Johnson to $165 and kept his Buy rating following Q3 results. Toung says the top-line growth was driven by oncology and immunology drugs, products gained through the Actelion acquisition, and improved performance in the Consumer segment. The analyst is also positive on the company's strategy of boosting growth through acquisitions and shedding of slower-growth businesses.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
10/19/17
FBCO
10/19/17
NO CHANGE
Target $154
FBCO
Outperform
Johnson & Johnson price target raised to $154 from $147 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Johnson & Johnson to $154 from $147 following Q3 results. The analyst reiterates an Outperform rating on the shares.
10/26/17
JANY
10/26/17
DOWNGRADE
Target $27
JANY
Sell
Pacira downgraded to Sell from Neutral at Janney Capital
Janney Capital analyst Ken Trbovich downgraded Pacira Pharmaceuticals (PCRX) to Sell and cut his price target for the shares to $27 from $36. Symphony Health data shows no signs Exparel growth is taking hold, Trbovich tells investors in a research note. The analyst sees no evidence of a benefit from Johnson & Johnson's (JNJ) Depuy Synthes sales force and believes Q3 estimates are too high. Deterioration in Exparel growth is likely to lead management to cut their full outlook when reporting Q3, Trbovich writes. He sees 20% downside from current share levels. Pacira closed yesterday down 5% to $31.85.
GSK GlaxoSmithKline
$34.84

0.18 (0.52%)

11/27/17
UBSW
11/27/17
UPGRADE
UBSW
Buy
GlaxoSmithKline upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded GlaxoSmithKline to Buy with an unchanged price target of 1,550p. Concerns of continuing earnings decline and the dividend sustainability are now overdone, Leuchten tells investors in a research note. The analyst believes the dividend looks secure and views the 6% forecast yield as "handsome."
11/24/17
DBAB
11/24/17
NO CHANGE
Target $59
DBAB
Hold
Deutsche cuts Merck target to $59 on competition from AbbVie, GSK
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax. The stock closed Wednesday up 10c to $54.37. Demand trends for Merck's hepatitis C virus drug Zepatier have continued to decline as AbbVie's (ABBV) Mavyret has gained traction, Gilbert told investors in a research note. The analyst also assumes "significant pressure" on Merck's shingles vaccine Zostavax from the near-term competitive launch of GlaxoSmithKline's (GSK) Shingrix. Gilbert views Merck's risk/reward as fairly balanced and he keeps a Neutral rating on the shares.
11/30/17
ARGS
11/30/17
NO CHANGE
Target $40
ARGS
Buy
GlaxoSmithKline price target lowered to $40 from $50 at Argus
Argus analyst John Eade lowered his price target on GlaxoSmithKline to $40 but kept his Buy rating, saying that the 10% decline in stock price over the past quarter presents a buying opportunity. Eade attributes the decline to the company lagging its peers in moving beyond the patent cliff as well as pricing pressure and generic threats to its respiratory blockbuster Advair/Seretide. However, the analyst says the new CEO should be able to accelerate the efforts to leverage the company's strengths, which include consumer products, vaccines and anti-infectives.
11/27/17
11/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying he views Lowe's shares as more attractive following the third quarter beat. 2. T-Mobile (TMUS) upgraded to Buy from Neutral at MoffettNathanson. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS with analyst Michael Leuchten saying concerns of continuing earnings decline and the dividend sustainability are now overdone. 4. Ciena (CIEN) upgraded to Buy from Neutral at BofA/Merrill with analyst Tal Liani saying shares are at the low end of the historical range and the earnings growth profile is attractive. 5. Constellium (CSTM) upgraded to Outperform from Market Perform at Cowen with analyst Novid Russell saying the company's rapid deleveraging has allowed investors to focus on its significant growth projects, attractive end markets, and valuation discount relative to peers. Russell raised his price target to $13 from $11 on Constellium shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SNY Sanofi
$43.29

0.12 (0.28%)

12/06/17
BOFA
12/06/17
DOWNGRADE
BOFA
Neutral
Sanofi downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Graham Perry downgraded Sanofi to Neutral citing valuation and lack of earnings momentum into 2018.
12/01/17
MSCO
12/01/17
DOWNGRADE
MSCO
Underweight
Sanofi downgraded to Underweight from Overweight at Morgan Stanley
11/16/17
EVER
11/16/17
NO CHANGE
Target $445
EVER
Outperform
Regeneron price target lowered to $445 from $605 at Evercore ISI
Evercore ISI lowered its price target for Regeneron (REGN) to $445 from $605 given meaningful competitive threat to Eylea. For every dollar of U.S. Eylea sales lost to competition, Regeneron has to make up for it with two times as much revenue from the Sanofi (SNY) JV, it adds. The firm has an Outperform rating on Regeneron's shares.
11/15/17
LEHM
11/15/17
UPGRADE
LEHM
Equal Weight
Sanofi upgraded to Equal Weight from Underweight at Barclays
Barclays upgraded Sanofi to Equal Weight from Underweight saying valuation is back to more reasonable levels.
RBGLY Reckitt Benckiser
$17.78

0.21 (1.20%)

02/02/17
SBSH
02/02/17
NO CHANGE
Target $83
SBSH
Buy
Citi calls $90/share price not 'all that great' for Mead Johnson
A deal price for Mead Johnson (MJN) of $90 per share "doesn't seem all that great" given that the shares were at $92 back in July of 2016 and hit $105 in February 2015, Citi analyst David Driscoll tells investors in a research note after Reckitt Benckiser (RBGLY) confirmed overnight that it is in "advanced negotiations" to buy the baby formula maker for $90 per share. The analyst believes Mead shares could be valued at $112 in a takeover. "It is quite easy to wonder if Reckitt isn't coming along at a most opportune time when Mead's EBITDA is depressed, but on a road to recovery," Driscoll writes. The analyst thinks interest from other bidders is likely with press reports as recently as two weeks ago suggesting Nestle (NSRGY) had interest in Mead while other reports suggested interest from Danone (DANOY). Driscoll even ponders if Kraft Heinz (KHC) may "come out of the shadows." In pre-market trading, Mead shares are up 24%, or $16.50, to $86
02/02/17
WBLR
02/02/17
NO CHANGE
WBLR
Wyeth Nutrition deal implies $100/share price for Mead, says William Blair
William Blair analyst Jon Andersen says Nestle's (NSRGY) acquisition of Wyeth Nutrition a few years ago, done at 20 times EBITDA, implies a Mead Johnson (MJN) takeover price closer to $100 per share. Reckitt Benckiser (RBGLY) appears to have the financial capacity to get a deal done, Andersen tells investors in a research note after both the company and Mead confirmed the deal talks. The analyst has an Outperform rating on Mead.
02/06/17
RBCM
02/06/17
DOWNGRADE
RBCM
Underperform
Reckitt Benckiser downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital analyst James Edwardes Jones downgraded Reckitt Benckiser to Underperform with a price target of GBP 6,300.
07/06/17
JEFF
07/06/17
DOWNGRADE
JEFF
Hold
Reckitt Benckiser downgraded to Hold from Buy at Jefferies
Jefferies analyst Martin Deboo downgraded Reckitt Benckiser to Hold saying the recent share rally no longer leaves sufficient upside for a Buy rating. The analyst raised his price target to 8,400p from 7,750p.
NSRGY Nestle
$86.16

-0.48 (-0.55%)

11/21/17
WELS
11/21/17
NO CHANGE
WELS
Nestle acquisition of Hain makes sense, says Wells Fargo
Wells Fargo analyst John Baumgartner believes a Nestle (NSRGY) acquisition of Hain Celestial (HAIN) would make sense. Bloomberg last night reported that Nestle is among the companies exploring a purchase of Hain. Nestle would likely be a good fit for Hain's baby food, skin care and tea businesses, Baumgartner told investors earlier in a research note. The analyst sees "tax leakage" as a headwind for any deal and keeps a Market Perform rating on Hain with a $38 price target.
10/04/17
MSCO
10/04/17
NO CHANGE
Target $62
MSCO
Overweight
'Third Wave' coffee shops still too small to hurt Starbucks, says Morgan Stanley
Morgan Stanley analyst John Glass said the emergence of more "Third Wave" coffee shops have fueled competitive fears for Starbucks (SBUX), but he contends that the absolute numbers of specialty chains with 10 or more units remain small and most data sources show smaller chains and independents are flat to slightly declining in number. Recent high profile investments in specialty coffee, such as JAB's purchases of Stumptown and Intelligentsia and Nestle's (NSRGY) majority stake in Blue Bottle, are making headlines, but the brands' competitive relevance may be overstated, Glass tells investors. The analyst, who added that the last time McDonald's (MCD) pushed into specialty coffee it had "no discernable negative impact on Starbucks, and arguably even a positive one," keeps an Overweight rating and $62 price target on Starbucks shares.
08/16/17
PIPR
08/16/17
NO CHANGE
Target $92
PIPR
Neutral
Kraft Heinz could have interest in Nestle divestitures, says Piper Jaffray
Piper Jaffray analyst Michael Lavery expects Kraft Heinz (KHC) to pursue further consolidation, likely in packaged food, and believes potential divestitures from Nestle (NSRGY) could fit the company's criteria well. Such a deal could boost Kraft's international scale and provide synergy savings in its U.S. frozen supply chain, the analyst tells investors in a research note. He maintains a Neutral rating on Kraft Heinz shares with a $92 price target.
10/13/17
CHLM
10/13/17
NO CHANGE
Target $7
CHLM
Buy
Market just beginning to recognize Codexis opportunity, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt says Codexis (CDXS) has a "unique proprietary CodeEvolver protein engineering platform" that is being sought by large pharma names, citing yesterday's announcement of a partnership with Nestle (NSRGY). Hewitt says that despite the recent stock price appreciation, the increasing value of the company's development pipeline suggests the markets is just starting to recognize the opportunity. The analyst has a Buy rating and a $7 price target on the stock.

TODAY'S FREE FLY STORIES

CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

, LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

05:20
12/15/17
12/15
05:20
12/15/17
05:20
Recommendations
Campbell Soup, Snyder's-Lance analyst commentary  »

Campbell deal for…

CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$83.87

0.84 (1.01%)

05:16
12/15/17
12/15
05:16
12/15/17
05:16
Recommendations
Tesaro analyst commentary  »

Tesaro price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

05:13
12/15/17
12/15
05:13
12/15/17
05:13
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRC

First Republic

$88.54

-0.27 (-0.30%)

05:11
12/15/17
12/15
05:11
12/15/17
05:11
Downgrade
First Republic rating change  »

First Republic downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$83.87

0.84 (1.01%)

05:10
12/15/17
12/15
05:10
12/15/17
05:10
Hot Stocks
Tesaro announces availability of Zejula in Germany »

Tesaro announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCM

Hutchison China MediTech

$31.11

0.05 (0.16%)

05:09
12/15/17
12/15
05:09
12/15/17
05:09
Hot Stocks
Hutchison China MediTech initiates fruquintinib U.S. clinical trials »

Hutchison China MediTech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

, CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

05:09
12/15/17
12/15
05:09
12/15/17
05:09
Recommendations
Snyder's-Lance, Campbell Soup analyst commentary  »

Snyder's-Lance worth…

LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$57.31

-0.38 (-0.66%)

05:07
12/15/17
12/15
05:07
12/15/17
05:07
Hot Stocks
CSX announces medical leave of CEO, COO James Foote named acting CEO »

CSX announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

05:03
12/15/17
12/15
05:03
12/15/17
05:03
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

05:00
12/15/17
12/15
05:00
12/15/17
05:00
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco Products

$53.13

-0.6 (-1.12%)

04:59
12/15/17
12/15
04:59
12/15/17
04:59
Upgrade
Sonoco Products rating change  »

Sonoco Products upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$48.03

-0.22 (-0.46%)

, AVY

Avery Dennison

$114.28

-0.09 (-0.08%)

04:58
12/15/17
12/15
04:58
12/15/17
04:58
Upgrade
Sealed Air, Avery Dennison rating change  »

Sealed Air upgraded to…

SEE

Sealed Air

$48.03

-0.22 (-0.46%)

AVY

Avery Dennison

$114.28

-0.09 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.80

-0.1 (-0.92%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Initiation
Hi-Crush Partners initiated  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$52.49

-0.35 (-0.66%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
MetLife to hold a conference call »

Investor outlook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

  • 12

    Jun

04:55
12/15/17
12/15
04:55
12/15/17
04:55
General news
Industrial Production Capacity Utilization Rate to be reported at 09:15 »

November Industrial…

04:55
12/15/17
12/15
04:55
12/15/17
04:55
General news
Breaking General news story  »

Week of 12/15…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Cable, Media &…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

DIS

Disney

$110.57

2.96 (2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

04:55
12/15/17
12/15
04:55
12/15/17
04:55
General news
Industrial Production to be reported at 09:15 »

November Industrial…

ADRNY

Ahold Delhaize

$21.69

-0.14 (-0.64%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Ahold Delhaize management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

BASFY

BASF

$27.57

-0.17 (-0.61%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
BASF management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CUTR

Cutera

$47.20

-1.3 (-2.68%)

, TESO

Tesco

$3.70

-0.25 (-6.33%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Hot Stocks
Cutera to replace Tesco in S&P 600 at open on 12/15 »

MidCap 400 constituent…

CUTR

Cutera

$47.20

-1.3 (-2.68%)

TESO

Tesco

$3.70

-0.25 (-6.33%)

NBR

Nabors Industries

$5.58

-0.23 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

RCKZF

Rocket Internet

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Rocket Internet management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

PJT

PJT Partners

$44.10

-0.24 (-0.54%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
PJT Partners management to meet with Sandler O'Neill »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

JAGX

Jaguar Health

$0.13

0.0068 (5.52%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Jaguar Health to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.